Oxford Cannabinoid Technology partners with Simbec-Onion on milestone FIH Phase I study

Simbec-Orion is honoured to have been trusted by Oxford Cannabinoid Technologies to run this milestone first-in-human Phase1 clinical trial of its lead compound, OCT461201 for Postherpetic Neuralgia (PHN) & Irritable Bowel Syndrome.

Chief Scientific Officer, Valentino Parravicini recently discussed the significance of partnering with Simbec-Orion for the first-in-human Phase 1 clinical trial of the lead compound, OCT46120. During the interview, he shares the process his team undertook for the selection of their clinical partner, and what drove their final decision.

Back to News Archive